Navigation Links
NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011
Date:5/4/2011

ue $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2011 and December 31, 2010--Common stock: par value $0.001, 100,000,000 shares authorized; 54,678,198  and 54,043,317 shares issued as of March 31, 2011 and December 31, 2010, respectively5453Additional paid-in capital473,117465,642Accumulated deficit(314,436)(308,426)Accumulated other comprehensive income31485Treasury stock, at cost: 447,929 and 325,104 shares as of March 31, 2011 and December 31, 2010, respectively(7,903)(5,225)Total stockholders’ equity151,146152,129Total liabilities and stockholders’ equity$ 287,195$
286,094NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited)Three Months EndedMarch 31,20112010Cash flows from operating activities:Net loss

$ (6,010)$ (8,999)Adjustments to reconcile net loss to netcash used in operating activities:Depreciation and amortization

5,6905,464Stock-based compensation

3,4142,892Other

874477Changes in operating assets and liabilities:Accounts receivable

(667)(766)Inventory

(6,671)(6,654)Prepaid expenses and other assets

(324)(556)Accounts payable

3,985940Accrued expenses and other liabilities

(3,887)2,521Deferred revenues

6023,065Net cash used in operating activities

$ (2,994)$ (1,616)NxStage Medical, Inc.Revenues by Segment(in thousands)Three Months EndedMarch 31,20112010System One segment  Home

$
26,045$
9,043  Critical Care

7,4386,059Total System One segment

33,48325,102In-Center segment

17,08115,306Total

$
50,564$
40,408NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited)Three Months EndedMarch 31,20112010Net loss

$
(6.0)$
(9.0)Less: Depreciation, amortization, interest, and taxes

7.16.9Less: Adjusting items*

-0.8Adjusted EBITDA gain (loss)

$
.1$
(1.3)* Adjusting items include sto
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. BMP Sunstone Reports Second Quarter 2008 Financial Results
9. ULURU Inc. Reports Second Quarter 2008 Financial Results
10. Immtech Reports Fiscal First Quarter 2009 Results
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 EnGeneIC, Ltd. ... the treatment of cancer through the targeted delivery ... that, together with the Asbestos Disease Research Institute ... New South Wales (NSW) Premier,s Award for Excellence ... are the hospitals that will be involved in ...
(Date:9/15/2014)... State University have developed a technique for controlling the ... voltages, opening the door to a new generation of ... hinges on the fact that the oxide "skin" of ... acts as a surfactant, lowering the surface tension ... researchers used a liquid metal alloy of gallium and ...
(Date:9/15/2014)... of carbon nanotubes is neat, but Rice University scientists are ... in new fibers created at Rice line up like a ... Angel Mart and his colleagues. , The tricky bit, according ... the journal ACS Nano , is keeping the densely ... , Left to their own devices, carbon nanotubes form clumps ...
(Date:9/15/2014)... MORRISVILLE, NC (PRWEB) September 15, 2014 ... newly developed deep imaging OCT system for the optical ... , The EnvisuTM S4410 SDOCT for Contact ... measurements for standard and high complexity contact lens, IOL ... allows imaging of a complete contact lens immersed in ...
Breaking Biology Technology:EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Researchers control surface tension to manipulate liquid metals 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2
... High-quality plasmid DNA for all demanding ... Jeff Braman ,Stratagene , A new ... and reliably isolate,high-purity plasmid DNA. The convenient ... flow columns, and alcohol precipitations, while,easily accommodating ...
... versatile kit for site-directed mutagenesis of,large plasmids ... Holly Hogrefe ,Jeff Braman ,Stratagene , ... efficiencies exceeding 80%. We have created a ... The QuikChange XL,site-directed mutagenesis ...
... accurate using the Quantos cell,proliferation assay kit ... LLC , The Quantos cell proliferation ... the number of cells present in,various tissue culture ... well the kit,performed compared to another commercial fluorescence-based ...
Cached Biology Technology:A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 2A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 3A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 4High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 2High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 3High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 4Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 2Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 3Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 4
(Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
(Date:9/15/2014)... indicates that lowland tapir populations may continue to drop ... Researchers from the Office National de la Chasse et ... Diego Zoo Global reviewed data retrieved from camera traps ... years and compared this data to current harvest rates ... hunting tapirs in French Guiana," said Matthias Tobler, a ...
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... has made significant inroads into uncovering the genetic basis ... with overall obesity and 13 that affect fat distribution. ... a million participants, the largest genetic investigation of human ... (Genetic Investigation of ANthropometric Traits) consortium which consists ...
... may be on the way for millions of people on ... bugs. Scientists have reported a key advance in efforts to ... as a major nuisance to homeowners and a devastating pest ... a fungus that infects a common weed and found that ...
... ovarian cancer has shown single agent activity with durable disease ... international research group has reported. Dr Ursula Matulonis ... of the single-agent trial of the drug, called MLN8237, in ... for Medical Oncology (ESMO). MLN8237 selectively inhibits ...
Cached Biology News:Studies provide new insights into the genetics of obesity and fat distribution 2Studies provide new insights into the genetics of obesity and fat distribution 3Progress toward first commercial repellent for East Coast's stinker 2Investigational ovarian cancer drug shows promise against platinum resistant disease 2